The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotech company specializing in autoimmune therapies, has agreed to sell its Huntsville, Alabama manufacturing operations to Ampersand Capital ...

Nektar said it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent ...